There’s much to marvel at - and just as much to dislike - in our culture of instant gratification.
G’day! Would you like the good news first? It’s Monday morning, meaning another working week is upon us. Excellent! The bad? Well, we only have five days of it until the inevitable blasted weekend. Let’s make the most of it while we can, then, and let’s kick things off with the week’s top five pharma headlines.
Good Morning! The weather outside the Formedix UK offices can only be described as a deluge - which is appropriate, given that we’re battling a perfect storm of pharma news today. There’s so much happening! Let’s just get straight to it, shall we?
When submitting clinical data to a regulator in electronic format, you’ll need to include metadata - data about the data - in the form of a Define-XML. This CDISC-format file helps the reviewer who’ll eventually approve or reject your application by describing the format and content of the data submitted.
Morning! I’m sure you know the drill by now, but in case you don’t: here are the biggest pharma news stories of the week - digested and distilled for your perusal. Enjoy!
Morning! Here’s what you need to know in the pharma world today:
Ahead of this year’s DIA 2015 Annual Meeting, Formedix commissioned a series of three interviews with some of our CDISC standards experts. In the third, Consultancy Manager Darren Bill discusses Formations, the token-based payment system for Formedix On Demand Services, and its advantages over traditional user licenses.
Good Morning! We hope you had an enjoyable holiday weekend and managed to wring every last bit of fun out of those four glorious days. Of course, you’ll have been far too busy having fun to keep up with the latest developments on Planet Pharma, so we’ve been trawling the weekend’s news to bring them to you. Enjoy!
Ahead of this year's DIA 2015 Annual Meeting, Formedix commissioned a series of three interviews with some of our CDISC standards experts. In the second, our man in Japan Masahiro Hayashi talks about the country's looming CDISC deadline, and what it means for its pharmaceutical companies.